U.S. biologics CDMO, Bionova Scientific of the Asahi Kasei Group, expands manufacturing capacity
share
Article Summary
Asahi Kasei Medical’s U.S. subsidiary Bionova Scientific, a full-service biologics CDMO, has decided to expand its process development and GMP biologics manufacturing capacity.
Under the Asahi Kasei Group’s medium-term management plan (MTP) for fiscal 2024 focused on the theme “Be a Trailblazer”, the bioprocess business of Asahi Kasei Medical is one of 10 Growth Gears (GG10), businesses to lead the next phase of growth. Asahi Kasei Medical has obtained further growth opportunities by leveraging its customer base and brand strength to enter the CRO (contract research organization) business in 2019 and CDMO (contract development and manufacturing organization) business in 2022, in addition to expanding its established business such as Planova™ virus removal filters with the expansion of the biopharmaceuticals market.
Bionova Scientific is well regarded for its capability of process development for complex next-generation antibody based drugs* whose manufacture tends to be difficult. There is also an increase in the requests relating to its antibody drug manufacturing process development and GMP production. To accommodate such customer needs in future, Bionova Scientific has decided to expand its process development and GMP manufacturing capacity. As a result, GMP manufacturing capacity will quadruple.
Through its provision of innovative and exceptionally reliable products and services, Asahi Kasei Medical aims to contribute to the improved safety and the stable supply of biotherapeutics, while further driving the growth of the Health Care sector of the Asahi Kasei Group.
Comments
Leave A Comment
Leave a Reply
